Status:

TERMINATED

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Conditions:

Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether p53 vaccination followed by high dose chemotherapy and autologous HCT and T cell therapy significantly induces immune responses resulting in 1-year su...

Eligibility Criteria

Inclusion

  • Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis.
  • Measurable disease at the time of initial therapy
  • Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy.
  • Responsive disease to standard chemoradiation therapy as defined by RECIST
  • Patients with CR after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation
  • CBC with an absolute neutrophil count (ANC) \>/= 1,000/uL, hemoglobin \>/= 8.0 g/DL and platelet count \>/= 75,000/uL.
  • Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial.
  • Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than 1.5X the upper limit of normal.
  • Creatinine clearance of \>/= 60 mL/min
  • Pulmonary: DLCO greater than 50%
  • Cardiac: left ventricular ejection fraction greater than 45%

Exclusion

  • Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation
  • Pregnant or lactating woman
  • HIV infection confirmed by NAT
  • Common variable immunodeficiency
  • Active CNS malignancy
  • Active bacterial, fungal or viral infection
  • Unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care
  • Prior history of autologous or allogeneic hematopoietic cell transplantation
  • Presence of protocol specific comorbid conditions

Key Trial Info

Start Date :

May 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2010

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT00776295

Start Date

May 1 2007

End Date

August 1 2010

Last Update

January 24 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

HLeeMoffitt

Tampa, Florida, United States, 33612

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer | DecenTrialz